NCT03916029 (HfLI) is a NA clinical trial of facilitator in Otitis Media, sponsored by Menzies School of Health Research.

Who is sponsoring NCT03916029?

NCT03916029 is sponsored by Menzies School of Health Research.

What drugs are being tested in NCT03916029?

Interventions in NCT03916029: facilitator.

What condition does NCT03916029 study?

NCT03916029 studies Otitis Media, Conductive Hearing Loss.

Is NCT03916029 still recruiting?

NCT03916029 is currently completed. Last updated 21 May 2025.

Last reviewed 2025-05-21 · How we verify

NCT03916029: HfLI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hearing for Learning Initiative - a Health Facilitator Model for Otitis Media

Completed NA Last updated 21 May 2025

What this trial tests

NA trial testing facilitator in Otitis Media in 18 participants. Completed in 31 December 2024.

Timeline

3 February 2019

Primary endpoint
30 June 2024

31 December 2024

Quick facts

Lead sponsor	Menzies School of Health Research
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	health services research
Enrollment	18
Start date	3 February 2019
Primary completion	30 June 2024
Estimated completion	31 December 2024
Sites	20 locations across Australia

Drugs / interventions tested

facilitator

Conditions studied

Otitis Media — all drugs for Otitis Media →
Conductive Hearing Loss — all drugs for Conductive Hearing Loss →

Sponsor

Menzies School of Health Research

Who can join

Adults 1 Week to 16, any sex, with Otitis Media or Conductive Hearing Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Hearing for Learning Initiative is a stepped-wedge cluster randomised controlled trial. The HfLI will implement and rigorously evaluate an innovative community-based service-enhancement model of ear and hearing health, in partnership with participating communities and health and education services. This initiative will address the following research question: In urban, rural and remote Aboriginal communities in the Northern Territory, does employment, training and integration of local Ear and Hearing Clinical and Education Support Officers into health and education services (the Hearing for Learning initiative), compared to current practice, increase the proportion of children who receive an ear assessment, reduce the prevalence of ear and hearing problems and improve education outcomes of Aboriginal and Torres Strait Islander children, during a four year trial period?

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A community-based service enhancement model of training and employing Ear Health Facilitators to address the crisis in ear and hearing health of Aboriginal children in the Northern Territory, the Hearing for Learning Initiative (the HfLI): study protocol for a stepped-wedge clust
Kong K, Cass A, Leach AJ, Morris PS, et al · · 2021 · cited 8× · PMID 34134736 · DOI 10.1186/s13063-021-05215-7
A workforce enhancement model for Australian remote community Primary Health Care services: implementation of a stepped-wedge cluster randomised trial (SW-CRT).
Leach AJ, McCullough A, Websdale E, Su JY, et al · · 2026 · PMID 41612286 · DOI 10.1186/s12913-025-13743-0

Verify or expand the search:

Other recruiting trials for Otitis Media

Currently open trials in the same condition.

NCT06731660 — Digital Otoscope Versus Education and Feedback for Otitis Media in Young Children · NA · active not recruiting
NCT05915078 — Evaluation of Outcomes Following In-office Tympanostomy Using the Tula® System: a Prospective, Multi-center Registry · recruiting
NCT05641285 — Diagnostic Utility of Otosight Middle Ear Scope · active not recruiting
NCT06260618 — Effect of Chitodex Gel in Tympanoplasty Surgery · NA · recruiting

Other Menzies School of Health Research trials

Trials by the same sponsor.

NCT07468526 — An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria · Phase 3 · not yet recruiting
NCT07468513 — Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases. · Phase 4 · recruiting
NCT06148792 — A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria · Phase 3 · recruiting
NCT05879224 — Short Course Primaquine for the Radical Cure of P. Vivax Malaria - Indonesia · NA · completed
NCT05629416 — The Communicate Study Partnership · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03916029 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Menzies School of Health Research
Last refreshed: 21 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03916029.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing